ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 628,80
0,76%
Dow Jones
38 826,95
0,13%
DAX
18 131,97
0,32%
Brent Oil
84,725
0,98%
Bitcoin
64 412,45
-3,12%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) Actualités

VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VNDA
DateHeureSourceTitreSymboleSociété
13/06/202422h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
13/06/202416h02PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
06/06/202415h24PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.NASDAQ:VNDAVanda Pharmaceuticals Inc
30/05/202423h20PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
30/05/202422h48PR Newswire (US)Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®NASDAQ:VNDAVanda Pharmaceuticals Inc
29/05/202420h17PR Newswire (US)Vanda Pharmaceuticals Announces Presentations at SLEEP 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202422h46PR Newswire (US)Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its ShareholdersNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202422h31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202422h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VNDAVanda Pharmaceuticals Inc
15/05/202414h45PR Newswire (US)Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion SicknessNASDAQ:VNDAVanda Pharmaceuticals Inc
13/05/202422h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
09/05/202413h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202422h01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202422h30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202414h05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
23/04/202401h13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202416h21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202415h02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202416h25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202400h10PR Newswire (US)Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I DisorderNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202413h00PR Newswire (US)Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaNASDAQ:VNDAVanda Pharmaceuticals Inc
05/03/202403h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
08/02/202413h19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VNDAVanda Pharmaceuticals Inc
07/02/202422h02PR Newswire (US)Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
31/01/202422h30PR Newswire (US)Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
31/01/202415h00PR Newswire (US)Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of OnychomycosisNASDAQ:VNDAVanda Pharmaceuticals Inc
30/01/202418h35PR Newswire (US)Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
26/01/202404h05PR Newswire (US)Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.NASDAQ:VNDAVanda Pharmaceuticals Inc
25/01/202419h07PR Newswire (US)Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and HepatologyNASDAQ:VNDAVanda Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VNDA

Dernières Valeurs Consultées

USOTC
ALAN
Alanco Technologies (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés